Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.
Harvoni (ledipasvir/sofosbuvir) may become a potential treatment for children with chronic hepatitis C virus (HCV) infection and adults with hepatitis B virus (HBV), according to results of two clinical trials ... Read more
Despite official recommendations, most Americans born between 1945 and 1965 aren’t being tested for hepatitis C virus (HCV). That’s according to a new study, “Recent Hepatitis C Virus Testing Patterns Among Baby ... Read more
A restrictive Medicaid policy in many states limits hepatitis C virus (HCV) treatment to patients with severe disease, which leads to suboptimal treatment outcomes, high patient burden, and excessive costs. Now, ... Read more
Treatments combining Benitec Biopharma’s investigative agents — BB-101, BB-102 or BB-103 — with current standard of care may be a way of treating hepatitis B virus (HBV) infection, according to results obtained ... Read more
Researchers developed mathematical models to predict the association between the transmission of HIV and hepatitis C virus (HCV) infection transmission among people who inject drugs. The findings obtained may help ... Read more
Gilead Sciences Canada has been awarded this year’s Prix Galien Canada–Innovative Product Award for the development of Harvoni (ledipasvir/sofosbuvir), a once-daily combination pill for the treatment of chronic genotype 1 hepatitis ... Read more
Top-line results from four global Phase 3 clinical studies (POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4), led by Gilead Sciences, showed that the combination of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) — inhibitors of viral activity — can ... Read more